The ability to see the world around us is a gift that’s easy to take for granted, until it’s threatened by the onset of a devastating eye disease. For those facing the reality of vision loss, ophthalmic research represents a beacon of hope, offering the promise of new treatments and therapies to preserve or restore
01.02
2024
Phoenix-Micron, Inc. Announces Exclusive North American Distribution of Striatech Products
Phoenix extends its product offerings in North America to include behavioral assays to evaluate the visual abilities of rodents Bend, OR, USA, January 25, 2024 – Phoenix-Micron, Inc. (“Phoenix”), recognized globally for its leadership in in vivo ophthalmic imaging of small animals, is proud to unveil its latest collaboration as the exclusive North American
29.11
2021
Phoenix MICRON Spins out of Phoenix Technology Group to Better Serve Eye and Eye-Brain Researchers Globally
Bend, OR, USA, November 29, 2021 — The newly formed company, Phoenix-Micron, Inc., announced today it has completed the spin-out of the Phoenix MICRON® imaging platform from Phoenix Technology Group. This move is designed to increase focus and innovation in products designed to serve the eye and eye-brain research community. The new company, Phoenix-Micron, Inc.
29.07
2021
Subretinal injection damage has implication for experimental control and treatment in rat model of retinopathy of prematurity
In their 2017 article, “Effect of subretinal injection on retinal structure and function in a rat oxygen-induced retinopathy model,” Becker et al used the Phoenix MICRON® IV fundus camera, Phoenix MICRON® OCT2 and corresponding layer analysis software Insight 2D, and the Phoenix MICRON® focal ERG to find that subretinal injection of saline or even introduction
25.03
2021
Therapeutic target for retinal degeneration studied with the Phoenix MICRON® retinal structure and function tools
In their article, “Effect of MMP-9 gene knockout on retinal vascular form and function,” George et al study the effect of knocking out a matrix protein in a mouse model of retinitis pigmentosa using the Phoenix MICRON® platform including OCT, and Ganzfeld ERG. The combination of the Phoenix MICRON® fundus images, OCT revealing the layers,
29.09
2020
RPE mutations lead to retinal hypopigmentation, vasculature changes, and decreased function
In their paper, “The microphthalmia-associated transcription factor (Mitf) gene and its role in regulating eye function,” García-Llorca et al use the Phoenix MICRON® IV to examine the outer eye appearance, retinal pigmentation, and retinal vasculature through fluorescein angiography to study several different mouse mutants. Combined with electroretinography and histology, the fundus images tell a story